
MiMedx Group Launches EPIEFFECT for Hard-to-Heal Wounds
MiMedx Group, Inc. (Nasdaq: MDXG), a leading name in the healthcare industry, has announced that the company has launched EPIEFFECT™ an addition to its wound care solutions. EPIEFFECT is designed to meet the demands of clinicians facing the challenging task of treating acute and chronic hard-to-heal wounds. These wounds, such as diabetic foot ulcers (DFUs) and venous leg ulcers (VLUs), often present complex clinical scenarios, requiring treatment solutions. One positive feature of EPIEFFECT is its thick, tri-layer configuration, designed to secure grafts in place with sutures effectively. This feature is especially valuable for wounds with deep or tunneling characteristics, providing clinicians with a versatile tool to address a wide range of wound types.
EPIEFFECT is a lyophilized human placental-based allograft consisting of amnion and chorion membranes, while also retaining the intermediate layer. This innovative product is intended for use as a barrier, providing a protective environment in acute and chronic wounds. EPIEFFECT offers a biocompatible human extracellular matrix (ECM) enriched with more than 300 regulatory proteins. It is available in a variety of sizes, ranging from 6 cm² to 49 cm². Importantly, EPIEFFECT is listed on the Medicare Part B Average Sales Price File, effective October 1, 2023, at a price of $530 per square centimeter providing access to patients.
According to the American College of Surgeons it is estimated that in the United States it is estimated that 6.5 million individuals suffer from non-healing wounds due to various causes. The global chronic wound care market is estimated at approximately $13 billion based upon varied sources.